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                        Knowledge is the foundation of medicine but so is compassion, 
                        one cannot exist without the other 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                    To Michelle, Melanie, Melodi  
                                                                                             and Filip, 
ABSTRACT 
Unexplained infertility, one of the common gynecological disorders, affecting 10 to 15 
% of women worldwide. Recurrent pregnancy loss affects approximately 1 to 3 % of 
pregnant women with an unknown etiology in 50 % of cases. Endocrine dysfunctions, 
including thyroid dysfunction, are one of the related factors to female reproductive 
disturbances. The aim of the thesis was to explore the importance of thyroid function and 
endometrial factors for implantation and pregnancy. 
Three groups of pregnant women, one group with high risk (n = 88) was compared to a 
low-risk (n = 511) and a general screening group (n = 699) to study the incidence of 
subclinical hypothyroidism and hypothyroidism, defined as TSH < 2.5 mIU/L. Women with 
recurrent pregnancy loss, (n = 165), and controls, (n = 289), were included in genetic analysis 
and gene expression array of endometrium, (n = 4 and n = 5 respectively). Infertile women (n 
= 19) and fertile women were included to study thyroid-related proteins in endometrium (n = 
28) and Fallopian tube (n = 13). Human embryos, (n= 36), were used to study the effect of 
thyroid hormone on embryo development. 
Thyroid stimulating hormone (TSH), free thyroid hormone (fT4) and TPO antibodies 
(TPO-Ab) levels were analyzed by use of immunological methods. Genetic variations in the 
HABP2 gene was performed by use of TaqMan SNP Genotyping Assays. Gene expression 
array was used to study mRNA in endometrium of women with recurrent miscarriage at the 
time of implantation. Immunohistochemistry was used to analyze the presence and 
distribution of thyroid related proteins in endometrium. Additionally, influence of thyroid 
hormone (T4) on the early embryo development was analyzed. 
 Approximately 10 % of all pregnant women, regardless of risk, had elevated TSH 
levels. Furthermore, hypothyroid women on levothyroxine supplementation had in almost 50 
% of cases inadequate treatment. There were no significant differences in the presence of 
polymorphism in HABP2 genes in comparison to fertile controls. In total, 124 genes were 
differently expressed in women with recurrent miscarriage mainly related to immunological 
processes, particularly shown by upregulation of IL8 in women with recurrent miscarriage. 
The infertile women showed lower protein staining of TRα1 and MCT8 in endometrium 
compared to the fertile women. Staining of thyroid related proteins was observed in all 
different parts of Fallopian tube. T4 supplementation showed improvement of blastocyst 
development in T4 added media.  
In conclusion, general screening for thyroid dysfunction during first trimester of 
pregnancy is needed to find all women in need to LT4 supplementation. Inflammatory events, 
especially IL8, might offer a clue to recurrent pregnancy loss while variations in the HABP2 
gene does not seem to be associated with recurrent miscarriage. The expression and 
distribution of thyroid-related factors in endometrium seem to be related to unexplained 
infertility. The presence of thyroid-related proteins in fallopian tube and the improvement of 
embryo development after T4 treatment suggest that a functional thyroid system is important 
form achievement of a normal pregnancy.  
 2 
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1. INTRODUCTION 
THYROID 
1.1.1 Thyroid hormones 
           Thyroid hormones (TH), thyroxine (T4) and 3,3’,5-triiodo-L-tyronin (T3), are secreted 
from and stored in the thyroid gland. Thyroid hormones regulate energy, homeostasis, cell 
proliferation, and carbohydrate-, fat- and protein- metabolism. 
  
1.1.2 The hypothalamic and the pituitary regulation of thyroid hormone 
secretion 
 
The production of THs is mainly regulated by the hypothalamic – pituitary – thyroid 
axis [1]. Thyroid stimulating hormone (TSH) stimulates the production of TH in response to 
thyrotropin releasing hormone, produced by the hypothalamus. Thyrotropin releasing 
hormone (TRH) is transported to the pituitary via the hypothalamic hypophyseal portal 
system. TSH and TRH are regulated by negative feedback by T3 and T4. Furthermore, 
thyroid hormone levels are under influence of other hormones such as glucocorticoids, 
somatostatin, dopamine, prolactin, estrogen and growth hormones (Figure 1). 
 
 
  Figure 1. The figure shows the hypothalamic-pituitary-thyroid axis.  
  10 
1.1.3 Thyroid stimulating hormone, TSH and TSH receptor 
 
           TSH is a heterodimeric glycoprotein hormone that shares the α-subunit with other 
glycoprotein hormones such as human chorionic gonadotrophin (hCG), follicle stimulating 
hormone (FSH) and luteinizing hormone (LH), but has a unique β-subunit. TSH exerts its 
effect by binding to the TSH-receptor (TSH R), which is located in the cell membrane of 
thyroid follicular cells. The TSH R is a member of the G-protein associated receptor family, 
similar to the hCG and LH receptors [2, 3]. TSH R expression has been shown in thyroidal 
tissue and also in extra-thyroidal tissues such as adipose tissue, testes, ovaries and 
endometrium [4, 5].  
 
1.1.4 Thyroid hormone secretion  
 
          Follicular epithelial cells located in the thyroid gland produce thyroid hormones, 
mainly T4. They are hydrophobic hormones that are to more than 99 % bound to proteins, 
mainly to thyroxine binding globulin (TBG). The free fractions of thyroid hormones (fT4, 
fT3), which mediate thyroid hormone action in target cells, are estimated to 0.02 % of total 
T4 and 0.30 % of total T3.  
The local enzymatic conversion of thyroid hormone in target tissues is regulated by 
iodothyronine deiodinases [6]. The majority of T3 in the circulation is derived from 
conversion of T4 by type 2 iodothyronine deiodinases (DIO2) and type 1 iodothyronine 
deiodinases (DIO1). The inactivation of T4 and T3 to reverse T3 (rT3) is mediated by type 3 
iodothyronine deiodinase (DIO3) [7].   
Cellular transport of thyroid hormone requires active transport across the plasma membrane. 
This is mediated through different members of mono carboxylate transporter (MCT) and 
organic anion transporting polypeptide (OATP) depending on target cells [8] . 
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1.1.5 Thyroid hormone receptor 
 
          Thyroid hormones exert their biologic effect through thyroid hormone receptors (TRs), 
which act as transcription factors to regulate gene expression [9]. TRs bind to a short DNA 
sequence of target gene called thyroid response element (TRE), which leads to transcription. 
By contrast, TRs interaction with the response elements, in absence of T3 leads to 
suppression of basal transcriptional activity [10] (Figure 2). 
                   
Figure 2. The diagram illustrates the action of thyroid hormone in the target cells. Thyroid hormone 
receptors (TRs), Thyroid response element (TRE), mono carboxylate transporter (MCT), organic 
anion transporting polypeptide (OATP), type 2 iodothyronine deiodinases (DIO2) and type 1 
iodothyronine deiodinases (DIO1). 
 
Thyroid receptors are encoded by two genes, TRα and TRβ, each with three isoforms, TRα1, 
TRα2 and TRα3 and TRβ1, TRβ2 and TRβ3 [11]. Thyroid receptors are expressed in most 
tissues and they have higher affinity to T3 than T4. TRα1 is predominantly expressed in 
brain, heart and skeletal muscles [11]. TRβ1 is widely expressed in different organs except 
testes[12] . TRα1, TRα2 and TRβ1 have been shown to be present in human endometrium [4, 
5].     
 
  12 
THYROID DYSFUNCTION  
 
          Change in serum concentration of TSH is the most commonly used indicator of thyroid 
dysfunction such as autoimmune thyroid dysfunction, hypothyroidism, subclinical 
hypothyroidism and hyperthyroidism.  
 
1.1.6 Hypothyroidism 
 
           Hypothyroidism is defined as low levels of thyroid hormone combined with elevated 
levels of TSH. Hypothyroidism can be due to low secretion of the hormone from the thyroid 
gland, primary hypothyroidism, or due to low levels of TSH, that is central hypothyroidism. 
The worldwide prevalence of hypothyroidism is between 0.6 to 12 per 1000 women and 1.3 
to 4 per 1000 men [13].  
Iodine deficiency is the most common cause of hypothyroidism worldwide [14, 15]. In iodine 
sufficient countries like Sweden, the most common thyroid disorder is chronic autoimmune 
thyroiditis, usually known as Hashimoto’s thyroiditis. The diagnosis of Hashimoto’s 
thyroiditis is confirmed by the presence of anti-thyroid peroxidase antibodies (TPO-Ab) [16]. 
Hypothyroidism can also be caused by previous treatment of Graves´ disease such as anti-
thyroid drugs, thyroidectomy or radioiodine treatment.   
Symptoms of hypothyroidism are nonspecific and vary due to the severity of the disorder. 
Dry brittle hair and nails are common in these patients who may also have symptoms of 
chilliness, fatigue, weight gain and slowing of higher mental function. Treatment of 
hypothyroidism is thyroid hormone (L-T4) substitution. 
 
1.1.7  Subclinical hypothyroidism 
 
           Subclinical hypothyroidism (SCH), defined as elevated serum levels of TSH combined 
with normal thyroid hormone levels [17]. Studies performed in the United States have shown 
a prevalence of 3 to 15 % of SCH. Women with SCH may have vague or nonspecific 
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symptoms or have symptoms similar to those with hypothyroidism. Women with TPO-Ab 
and elevated TSH levels are at higher risk of progressing from SCH to hypothyroidism and to 
development postpartum thyroiditis [18-21].  
 
1.1.8 Hyperthyroidism (thyreotoxicosis) 
 
          Hyperthyroidism is defined as elevated thyroid hormone levels combined with almost 
undetectable levels of TSH. It affects approximately 2.0 % of women and 0.2 % of men 
worldwide. The most common type of hyperthyroidism is Graves´ disease. This condition is 
due to stimulation of thyroid gland by TRAb on the thyroid follicular cells [18].   
Common symptoms of hyperthyroidism are weight loss, palpitations, tremulousness, heat 
intolerance, and anxiety. Physical findings such as tachycardia, thyroid enlargement and 
tremor are also seen. Treatment options are: anti-thyroid drugs, surgery and radioiodine 
treatment. 
 
THYROID DYSFUNCTION AND FEMALE REPRODUCTION 
 
1.1.9 Hypothyroidism  
 
          Women with hypothyroidism have low levels of sex hormone binding globulin 
(SHBG) and low levels of estrogen and testosterone [22]. Menstrual disturbances such as 
oligomenorrhea, amenorrhea and menorrhagia are common in hypothyroid women. These 
disturbances can partly be due to TRH-induced hyperprolactinemia and thus altered pulsatile 
GnRH secretion and partly due to defect hemostasis with low levels of coagulation factors. 
[23-25]. 
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1.1.10 Hyperthyroidism (thyrotoxicosis) 
 
          Thyrotoxicosis may lead to different symptoms ranging from normal menstrual cycles 
to menstrual irregularities such as menorrhagia, oligomenorrhea, amenorrhea, anovulation 
and reduced fertility [26, 27]. Women with Graves´ Disease have 2 to 3 times higher serum 
levels of estrogen and LH during all phases of the menstrual cycle, probably due to high 
levels of SHBG [27]. The production of testosterone and androstenedione is also increased in 
these women [28].  
 
THYROID AND PREGNANCY 
 
1.1.11 The change in thyroid hormone production during pregnancy 
 
          During early pregnancy, a 2-fold estrogen derived increase in TBG occurs which 
requires an increase in thyroid hormone production and a higher daily intake of iodine [29-
32] [33]. While the free fraction of thyroid hormone is slightly increased during the first 
trimester of pregnancy, the total serum levels of thyroid hormones are 1.5-fold higher in 
pregnant women than in non-pregnant women. The TSH levels have a transient fall during 
the first trimester of pregnancy due the thyrotrophic action of hCG [34], the lowest levels are 
seen around 10-12 weeks of gestation. In iodine sufficient areas the TSH levels will remain 
stable and similar to pre-gestational levels after the first trimester until the end of pregnancy 
(Figure 3). 
 
1.1.12 The iodine status in pregnancy 
 
           A higher intake of iodine is required in pregnancy due to an increased distribution of 
iodine to the feto-placental unite and an increase in renal iodine clearance [44, 45]. According 
to WHO, a daily iodine intake of 250 µg is recommended for pregnant women, compared to a 
daily intake of 150 µg in non-pregnant women [46]. 
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Figure 3. The diagram shows serum TSH and hCG as a function of gestational age, illustrated by 
Glinoer et al. JCEM 71:276 1990 
 
1.1.13 Thyroid hormones and fetus 
 
           Despite incorporation of iodine late in the first trimester of pregnancy, the fetus does 
not start to secrete its own thyroid hormones until 18
th
 to 20
th
 weeks of pregnancy. Thus, the 
fetus is totally dependent on the trans-placental passage of maternal thyroid hormone during 
the early stages of pregnancy [35, 36]. During pregnancy, maternal thyroid receptor 
antibodies can also affect the fetus and anti-thyroid drugs due to trans-placental passage 
(Figure 3). 
  16 
TSH
T3, T4
Thyroid-
Ab
Antithyroid
-Drugs
Iodine
T4, T3
 
Figure 4. The figure shows trans-placenta passage of thyroid hormones and thyroid hormone related 
factors. 
 
 The fetus normal growth and neurologic development is dependent on optimal levels of 
thyroid hormones. Thyroid hormones influence neurodevelopmental events, such as 
neurogenesis, myelination, dendrite proliferation and synaptogenesis [37, 38].  
 
THYROID DYSFUNCTION DURING PREGNANCY  
 
1.1.14 Hypothyroidism / subclinical hypothyroidism or isolated 
hypothyroxinemia  
 
        Untreated hypothyroidism has been associated with an increased risk of obstetric and 
fetal complications while this it is not the case for isolated hypothyroxinemia or SCH [39, 40] 
[41]. Hypothyroidism and SCH have been associated with adverse fetal and obstetric 
outcome such as miscarriages, preterm labor before 32 weeks of gestation, postpartum 
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hemorrhage, respiratory fetal distress, intrauterine growth retardation (IUGR) and 
neurological disorders [39, 40, 42-46]. However, there is less evidence that untreated SCH 
during pregnancy is associated with neurological disorders in the fetus [47].  
 
1.1.15 Hyperthyroidism   
 
           Untreated hyperthyroisim is associated with adverse pregnancy outcomes such as 
miscarriage, preeclampsia, IUGR and preterm delivery. Both thyroid antibodies and anti-
thyroid drugs have the ability to pass through placenta. Thereby, women with positive TRAb 
have higher risk of fetal complications even in euthyroid status [48]. Pregnancy with positive 
TRAbs, require careful monitoring of thyroid status and TRAbs and controls of the fetus 
(ultrasonography) during pregnancy. The change of the immune system during pregnancy 
leads to remission in Graves´ disease like many other autoimmune diseases with a risk for a 
postpartum relapsing [49].  
 
1.1.16 Gestational thyrotoxicosis 
   
            The production of TH increases during pregnancy due to secretion of hCG, with a 
peak during the 10
th
 to12
th
 weeks of gestation. hCG is a glycoprotein, which shares the alpha 
unites with TSH and can act as a TSH agonist. This leads to suppression of TSH and transient 
hyperthyroxinemia in the first trimester of normal pregnancy as well as multiple pregnancies 
and may cause hyperemesis gravidarum [50-52].  
 
1.1.17 Postpartum thyroid dysfunction  
 
            Postpartum thyroiditis is a destructive autoimmune disease with a prevalence of 5 to 9 
% and usually occurs within the first year after delivery. Women with diabetes mellitus type 
1 have a threefold higher risk of developing postpartum thyroiditis. Women with positive 
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TPO antibodies have 50 % risk of developing postpartum thyroiditis and an increased risk of 
developing a permanent hypothyroidism [17, 53, 54]. 
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2. FEMALE REPRODUCTIVE ORGANS  
 
The female reproduction organs include vagina, uterus, fallopian tubes and ovaries, as 
illustrated in Figure 5. 
 
              
         
 Figure 5. The female reproduction organs, (www.medlineplus.gov) 
 
THE UTERUS 
 
          The uterus consists of three anatomical parts from cranial to the caudal: fundus, corpus 
uteri and cervix uteri. The upper left and right side of the uterus, from the uterine horns, 
continue into the Fallopian tubes. The uterine wall consists of three layers from inside out, a 
thin lining of cells called endometrium: a thick smooth muscular layer called myometrium 
and an outer thin serosal layer called serosa.  
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2.1.1 The Endometrium  
 
          The endometrium is a dynamic tissue that, in fertile women, undergoes cyclic 
regeneration, differentiation and shedding each month under the influence of the ovarian 
hormones [55]. The endometrium can be divided into two morphologic layers, the functional 
layer where the implantation of blastocyst takes place and the basal layer, from where the 
monthly regeneration of endometrium takes place. Histologically, the functional layer of the 
endometrium is divided into an epithelial surface, which constitutes of a luminal and 
glandular epithelium and a layer of stromal connective tissue. The luminal epithelium 
provides the initial site of implantation for the developing embryo. The epithelial layer secrets 
several factors including glycoproteins, cell adhesive molecules and glycogen during 
secretory phase which are required for endometrium development and implantation of the 
embryo [56]. The stroma is composed of fibroblasts, vessels and leukocytes that vary in their 
number and cell structure due to menstrual phase [57]. The fibroblasts and endothelial cells 
produced several factors involved in implantation of embryo including vascular endothelial 
growth factor (VEGF), cytokines and extracellular matrix components [58-60]. The 
endometrial leucocytes mediate pro-inflammatory conditions during secretory phase and are 
part of remodeling of the immune system associated to implantation, which includes, 
macrophages, neutrophils, mast cells, T, B cells and uterine natural killer cells.  
 
THE FALLOPIAN TUBE  
 
        The Fallopian tubes are divided into four parts from the uterine horns to the ovaries: the 
interstitial part which transverses the uterine musculature, the isthmus and the ampulla which 
represents the major lateral part of the Fallopian tubes where fertilization of ovum takes 
place, and the infundibulum with its fimbriae where the released oocyte is captured (Figure 
5). The Fallopian tube wall consists of three distinct layers; the serosa, the muscularis 
mucosae, which is composed of two layers: an outer longitudinal and an inner circular layer, 
and the mucosa. The mucosa consists of a luminal epithelial lining, which contains both 
secretory and ciliated cells. The fertilized oocyte transports throughout the fallopian tubes 
with help of beating motion of the cilia in combination with smooth muscular contractions 
[61]. 
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THE OVARY  
 
           Each ovary is approximately four cm long and two cm wide. The outer layer of the 
ovary consists a single epithelium directly beneath that is a layer of connective tissue known 
as tunica albuginea. The ovarian stroma, consist of fibroblasts, collagen and elastin, forming 
the ovarian cortex. The ovarian medulla contains blood and lymphatic vessels.  
The number of the follicles is highest prior to birth, approximately seven million, thereafter 
they are gradually reduced to about one million at birth, and around 24 000 at 37 years of age, 
where after the number of oocytes will decline even more rapidly [62]. At this age the 
number of follicles is normally so low that the possibility of pregnancy is significantly 
reduced.   
 
2.1.2 Folliculogenesis                      
 
          A cyclig recruitment of a pool of follicles, which will subsequently develop during 
folliculogenesis [63]. During the primordial follicle,premature follicle, will be develop into an 
antral follicle, which will either be selected to a dominant follicle or undergo atresia. 
Folliculogenesis occurs in the cortex of the ovarry and it takes almost one year for a 
primordial follicle to develop into an ovulatory follicle.The primordial follicle consists of a 
primary oocyte, a surrounding layer of granulosa cells and a basal lamina. The oocyte in the 
primordial follicle starts the first stage of meiosis, which arrests at the end of the diplotene of 
miosis until puberty. The first stage of meiosis will be completed before ovulation and the 
dominant follicle will start the second stage of meiosis, which will be completed after 
fertilization. During folliculogenesis, the granulosa cells proliferate due to influence of 
gonadotropins and ovarian hormones. The stromal-like cells, which surround the basal 
lamina, develop into two layers known as theca interna and theca externa [64]. 
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2.1.3 The hypothalamus-pituitary regulation of sex steroid hormone secretion 
 
          The hypothalamus-pituitary-ovarian axis is a feedback system, which primarily 
regulates the menstrual cycle as it has been illustrated in figure 6 [65]. The two gonatrophins, 
follicle stimulating hormone (FSH) and luteinizining hormone (LH) regulate the secretion of 
ovarians hormones. The synthesis and secretion of these hormones by the anterior pituitary 
are regulated by a pulsatory secrition of hypothalamic-gonadotrophin releasing hormone 
(GnRH), which in turn is under influence of ovarians hormones. The main estrogen produced 
by the ovaries is estradiol, which have a direct feedback effect on the piutitary and the 
hypothalamos. During the late follicular phase, slithly after the peak of estrogen levels the 
peak of LH and FSH occurs which will induce ovulation. High levels of preogestrone 
postovulatory will suppress the gonadotropins (Figure 6) . 
             
 
                               
 
 Figure 6. A diagram of the hypothalamus -pituitary -ovarian axis with positive (+) and inhibitory (-) 
feedback loop. Gonadotropins releasing hormone (GnRH), Follicle stimulating hormone (FSH), 
Luteinizing hormone (LH). 
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2.1.1 The ovarian cycle  
 
        The follicular phase, is initiated by increase in FSH during the preceding luteal phase, 
which stimulates folliculogenesis and secretion of the three estrogens, estrone, estradiol, 
estriol of which estradiol is the mainly produced. During this phase, the estradiol levels will 
gradually increase and reach its peak during the late follicular phase. The follicle with highest 
number of FSH receptors and the highest production of estrogens is selected as the dominant 
follicle [66]. The remaining follicles will undergo atresia. After the LH surge, the dominant 
follicle will mature and rupture, and thereby, the oocyte will be released [64, 67] [68] The 
residual follicle rearranges to form a corpus luteum which secrets both progesterone and 
estrogen (figure 7) [65]. In case of pregnancy, the secretion of progesterone continues from 
corpus luteum i.e., “corpus luteum graviditate”, which resists 8 to 12 weeks when placenta 
take over the hormone production. In absence of a pregnancy, the corpus luteum vill 
degenerate and form a corpus albicans. The drop of progesterone and estrogen levels 
eleminate the negative feedback to the hypothalamo-pituitary axes (figure 6 and 7). 
Besides estrogen and progesterone, the ovary produces testosterone and other steroid and 
non-steroidal hormones such as inhibin A, B and anti-Müllerian hormone [69]. The anti-
Müllerian hormone is produced by the granulosa cells of the primordial and antral follicles, 
with a stable serum concentration during the menstrual cycle [70]. 
 
2.1.2  Endometrial differentiation during the menstrual cycle  
 
           The first menstruation, menarche, starts at the age of 8.5 to 13 years, at mid to late 
puberty. The ideal cycle length is 28 days, while the menstrual cycles in fertile women range 
from 21 to 34 days generally due to the variability during the follicular phase. During the 
menstrual cycle the monthly preparation of the endometrium for implantation occurs.  
The menstrual cycle can be divided into three phases due to endometrial changes: one 
degenerative phase called menstrual phase, one proliferative phase which corresponds to the 
ovarian follicular phase, and one secretory phase, which corresponds to the ovarian luteal 
phase [71]. The menstrual phase of the menstrual cycle is initiated by bleeding, due to 
contraction of blood vessels, which will results in necrotic changes and degeneration of the 
functional layer of the endometrium. The regeneration of endometrium starts with the gradual 
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rise in estrogen during the proliferative phase, which initiates mitotic activity of all cell 
components of the endometrium, which leads to a considerable thickening of the endometrial 
mucosa. After ovulation, the secretory phase, the production of both progesterone and 
estrogens by corpus luteum increase. During this phase the endometrium will be prepared for 
implantation of the embryo. Decidualization of the stromal cells which include edema, 
coiling of spiral arterioles, and remodeling of the stromal cells to secretory epithelioid-like 
decidual cells [72]. As a part of decidualization, a remodeling of maternal blood vessels 
occurs, which initiates infiltration and / or proliferation immune cells, primarily macrophages 
and uterine natural killer cells [73, 74]. These immune cells secrete metalloproteinase and 
cytokines that degrade the extracellular matrix [59, 75]. Progesterone is essential for 
maintenance of the decidualization of the estrogen-primed endometrium. In absence of 
pregnancy, degeneration of the endometrium starts after accumulation of inflammatory cells 
in the endometrium. During the late secretory phase, degeneration of the endometrium starts, 
the secretion of estrogen and progesterone has dropped to low levels, and the endometrium 
begins to shed [76, 77](Figure 7).  
        
 
Figure 7. The menstruation cycle and its related hormones: Gonadotropic hormones; Follicle 
stimulating hormone (FSH), Luteinizing hormone (LH). Gonadal hormones (estrogen and 
progesterone), Implantations window (WOI).  
 
 
   25 
3. IMPLANTATION 
 
Women have an estimated implantations rate of less than 30 % in a natural menstrual 
cycle. Implantation requires fertilization of a haploid oocyte by a haploid sperm in the 
Fallopian tube, development of the early embryo during its transport in the Fallopian tube and 
finally implantation of the embryo into the endometrium [78, 79].  
The fertilization of oocytes is initiated by fusion of membranes of sperm and oocyte when the 
sperm enter the oocyte forming zygote. This event takes place in the ampulla of the Fallopian 
tube. The embryo undergoes regulated mitotic cleavage and different developmental stages 
(morula, blastocyst) during its transport through the Fallopian tube (Figure 8).  
          
            Figure 8. The figure shows different developmental stages of human embryo. 
The blastocyst consists of an outer trophectoderm, an inner cell mass and a fluid-filled cavity 
i.e., the blastocyst cavity. The inner cell mass will develop into an embryo and its belonging 
structures like the amnion and the yolk sac while the trophectoderm will form the placenta.  
The endometrium is only receptive for the embryo during a limited time of the mid secretory 
phase i.e., “the implantation window” (WOI). During this phase, assumingly 7 to 9 days after 
the LH surge, the endometrium is transformed to a receptive phase under influence of 
progesterone. Implantation beyond this transient receptive period has been associated with 
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early pregnancy loss. A morphologic change in the endometrium during WOI is the 
appearance of pinopodes, which are cytoplasmic protrusions on the surface of endometrium, 
which have been proposed to be structural markers of endometrial receptivity. Many potential 
biomarkers that belong to different functional groups have been identified to be involved in 
implantation [80]. However, no specific biomarker for human implantation has yet been 
identified. 
                   
    Figure 9.  The figure shows the embryo-endometrial dialogue (A) before apposition and (B) after 
invasion. Groll J, Lessey B, Glob. Libr. women’s med., (ISSN: 1756-2228) 2009; 
DOI10.3843/GLOWN.10318 
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Around day 4 to 5 after fertilization, the morula enters the uterine cavity (Figure 8). 
Thereafter, the developing blastocyst orients towards the surface of the endometrium and 
forms a loose connection with the endometrium, named apposition [81]. Adhesion is the 
result of a stronger attachment of the embryo into the endometrium by penetration of 
trophoblast cells into the luminal epithelium. Thereafter the trophoblast cells will differentiate 
into cytotrophoblasts at the inside and syncytiotrophoblasts at the outside. The extravillous 
trophoblasts will breach into the uterine blood vessel walls to ensure provision of placenta 
blood supply. Soon thereafter syncytiotrophoblast cells will penetrate deeper in the 
endometrium beneath the decidua cells [82, 83]. Normal development of these events 
requires a dialog between the blastocysts and the decidualized endometrium the so called 
“cross-talk” (Figure 9) [84-86]. This dialog is mediated by several different molecules, 
including hCG interleukins and leukemia inhibitory factor (LIF), secreted both in paracrine 
and autocrine manners from the blastocyst and the endometrium [58, 81, 87-90].  
 
MEDIATORS OF IMPLANTATION 
 
Many potential biomarkers belong to different substances such as growth factors, 
adhesions molecules and prostaglandins, which have been proposed to be involved in 
implantation. Since the study of human implantation is unethical and therefore impossible, 
most information has been derived from cell culture and animal studies. One approach to 
reach more knowledge about implantation is by using gene expression arrays and 
bioinformatic tools to identify the transcriptomic signature of the receptive endometrium 
[91]. Altmäe and collogues have identified a network of molecules involved in implantation, 
which includes cytokines and their interactions with the cytokine receptor [92]. Chemokine 
receptors are not only expressed in leucocytes but also in human blastocyst and endometrium 
both prior to implantation and during implantation. These chemotactic proteins are involved 
in several important processes of implantation such as, angiogenesis, embryo development 
and maintenance of innate and adaptive immunity [86, 93]. One inflammatory mediator of 
implantation is IL8. The IL8 is involved in processes important for implantation such as 
chemotaxis, neutrophil activation and angiogenesis. Its’ receptors, CXCR1, has been seen to 
be up regulated in presence of a blastocyst [94]. Chemokines are important modulators for 
migration and activation of leukocytes particularly uNK cells and macrophages. The uNK 
cells and macrophages are involved in adaptation of immunity during pregnancy i.e., 
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fetomaternal tolerance, which is essential for a successful implantation of the allogeneic fetus 
and placenta [95, 96]. One of the known mechanisms in this process is an epigenetic change 
in stromal decidual cells, which leads to modulation of their capacity to produce chemokines 
responsible for T cell recruitment [97].  
 
3.1.1 Genetics factors associated with infertility  
 
           Genetic variations have been proposed to be involved in infertility and recurrent 
miscarriage [98-100]. The genomic material in all living organisms is made from four 
nucleotides: adenosine, cytidine, guanosine and thymidine. The inter-individual differences 
consist of a few variations in the DNA sequences in the human population [101]. When a 
single nucleotide in a DNA sequences is altered called SNP (single nucleotide 
polymorphism). However, there are only a few SNPs, which have impact on cell function and 
human health.  
A polymorphism in regulatory region of HABP2 gene, genotype in rs2240879 and 
rs1157916, has been associated to infertility [102]. The HABP2 gene contains 13 exons and 
spans 35 kb in chromosome region 10q25 to q26. One known polymorphism in the HABP2 
gene is Marburg I, SNP rs7080536 (Gly534Glu), in axon 13. The Marburg I, SNP has a 
frequency of 4.3 to 9% in the Caucasian population which is a result of replacement of a 
single nucleotide G by A in the protease domain. The Marburg I, SNP is associated with low 
proteolytic activity of the HABP 2 and thereby increases risk for late complications of carotid 
stenosis [103, 104]. 
 The HABP2 gene is one of the genes that have been identified to be involved in endometrial 
receptivity and female infertility. The HABP2 gene encodes HABP2 protein, also known as 
activators of coagulation factor VII, urinary plasminogen activator (UPA) and tissue factor 
pathway inhibitor (TFPI) [105, 106]. The HABP2 protein is involved in coagulation, 
fibrinolysis, tissue remodeling and acts as a vascular inflammatory factor. Furthermore, it has 
also been shown to be negatively involved in vascular integrity. In the female reproductive 
system, HABP2 protein is an extracellular serine protease, which binds hyaluronic acid and 
functions as an angiogenesis promoter in the extracellular matrix with a cyclic variation 
during the menstrual cycle [107]. The highest levels of HABP2 are correlated to time of 
growth and remodeling during the mid-proliferative and mid-secretory phase of the menstrual 
cycle [108]. A lower level of HABP2 in the endometrium in women with unexplained 
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infertility has been observed. Lower endometrial gene expression of HABP2 has even been 
observed in women with recurrent miscarriage [107, 109]. 
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4. INFERTILITY 
 
          Infertility has been defined as the inability to conceive after one year or more of regular 
intercourses without use of contraception. The monthly fecundity rate in fertile couples has 
been estimated to 10 to 15 % [110, 111]. Between 2 to 10 % of couples worldwide are unable 
to conceive a child while more than 10 to 25% suffer from secondary infertility, i.e. inability 
to conceive after one or more successful pregnancies. Infertility has strong association with 
mental disorders like depression and anxiety and psychosocial distress [112]. The American 
Society for Reproductive Medicine (ASRM) and the World Health organization (WHO) 
consider infertility as a reproductive disease and has recommended investigation and 
treatment after one year for women below the age of 35 years and six months for women over 
the age of 35 years. 
Infertility can be related to male or female factors or combinations of both. The female 
factors include: endocrine dysfunctions such as ovarian dysfunction including luteal phase 
deficiency, prolactinoma, thyroid dysfunctions and anatomical abnormalities such as tubal 
and peritoneal factors due to post inflammatory conditions. Other factors associated with 
infertility in women are endometriosis, polycystic ovary syndrome and thrombotic inherited 
diseases.  
The male factors include anatomical abnormality, previous infections, sperm abnormality, 
chromosomal abnormalities and lifestyle such as cigarette smoking and alcohol consumption 
[113].  The clinical examination and tests that couples undergo to detect possible etiology for 
infertility include semen analyses, with normal results according to the World Health 
Organization (WHO) criteria [114, 115]. Women need to have normal levels of serum TSH, 
prolactin, normal ovulation and a normal tubal passage either diagnosed by 
hysterosonosalpingography or laparoscopy on suspicion of endometriosis [116].  
Assisted reproductive technology (ART) involves methods used for treatment of couples with 
infertility such as clomiphene citrate or gonadotropin treatment in combination with 
intrauterine insemination, in vitro fertilization (IVF) or intracytoplasmic sperm injection 
(ICSI). Since development of IVF in 1978, which was acknowledged by awarding Dr. R. G 
Edwards the Nobel Prize in the 2010, the number of ART children has increased. Despite 
continuous development and optimization of ART, not all attempts to treat are successful 
[117, 118].  
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UNEXPLAINED INFERTILITY 
 
 In more than 10 to 30 % of cases the etiology of infertility remains unexplained [119, 
120] and defines as unexplained infertility. An individualized management of couple 
suffering from unexplained infertility has been recommended with opportunity to offering 
current treatment options including, expectant management, changing lifestyle and ART.   
 
RECURRENT MISCARRIAGE 
 
 One of the most common early pregnancy complications is loss of pregnancy during the 
first 20 weeks of pregnancy i.e. miscarriage, which occurs in approximately 15 % of all 
clinically confirmed pregnancies. Recurrent miscarriage is less common and affects 1 to 3 % 
of couples trying to become pregnant. It has been defined as three or more consecutive 
pregnancy losses up to the 20
th
 week of pregnancy (www.eshre.eu). 
Recurrent miscarriage has been related to multiple factors that factors include endocrine 
disorders such as untreated hypothyroidism, uncontrolled diabetes mellitus, luteal phase 
defect, polycystic ovarian syndrome (PCOS) and hyperprolactinemia. Other factors 
associated with recurrent miscarriage are anatomic abnormalities. Furthermore, inherited 
diseases such as autoimmunity including thyroid autoimmunity, antiphospholipid antibody 
syndrome (APS) and parental chromosomal abnormalities, antithrombotic inherited diseases 
such as factor V Leiden, mutation in the promoter region of the prothrombin gene and 
mutations in the gene encoding methylene tetrahydrofolate reductase (MTHFR) resulting to 
hyperhomocysteinemia, protein S and protein C and deficiencies in antithrombin, has been 
related to recurrent miscarriage. Although, none of these factors has been proven to cause 
recurrent miscarriage, they have only been suggested to increase the risk for recurrent 
miscarriage [121]. In majority of cases, approximately, in 50 % of cases the etiology of 
pregnancy losses remains unclear, which defines as unexplained recurrent miscarriage [122, 
123]. 
 
 
 
  32 
5. AIM OF THE STUDIES 
 
GENERAL AIM  
 
         The overall aim of the studies was to explore endocrine and paracrine factors related to 
female reproduction. 
 
SPECIFIC AIMS 
 
 -To detect the incidence of subclinical hypothyroidism and hypothyroidism in women during 
early pregnancy. 
- To detect associations between genetic variations in HABP2 gene with recurrent pregnancy 
loss. 
-To compare the endometrial gene expression profile in women with unexplained recurrent 
pregnancy loss with fertile controls. 
- To compare serum and endometrial levels of thyroid related factors in fertile women and 
women with unexplained infertility.  
- To explore the presence and distribution of proteins related to thyroid function in 
endometrium and Fallopian tubes  
-  To study the influence of T4 supplementation on in vitro development of the embryo. 
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6. MATERIALS AND METHODS 
 
ETHICS  
Study II and I were approved by the Regional Ethical Review Board in Stockholm 
(2009/2:6) and (2009/177-32) respectively. Study III was approved by the Regional Ethics 
Board in Stockholm and the Regional Ethical Board in Uppsala (2006/751-31/1-4 and 
2009/498-32). All participants gave informed oral and written consent prior to participation. 
Study IV was approved by the Regional Ethical Board in Stockholm and the Regional Ethical 
Board in Uppsala (2008/046/1 and 2012/339). The women who donated Fallopian tubes and 
endometrium gave their informed consent before participation. The human embryos were 
donated for research after 5 years limit storage has passed. Both partners of the couples 
involved signed an informed consent form after receiving oral and written information. All 
research was performed in accordance with relevant guidelines/regulation. 
 
MATERIAL  
 
6.1.1 Incidence of subclinical hypothyroidism and hypothyroidism during first 
trimester of pregnancy  
Women (n = 1298) up to 12 weeks and 6 days of pregnancy were screened for thyroid 
dysfunction except for hyopthyroxineamia. The women were enrolled at three participating 
antenatal care unites, two in the north of Stockholm, in high- income areas, and one in the 
south of Stockholm, at a mixed socioeconomic area. The incidence of thyroid dysfunction in 
a high risk group (n = 88), only women at risk of thyroid disease, was compared to a low risk 
(n = 511) and a general screening group (n = 699). The criteria for high-risk group were 
based on recommendation for screening, in Stockholm, at the time of the study, including, 
family history of thyroid dysfunction or previous treatment with LT4, propylthiouracil, 
methimazole, radioiodine, previous surgery, goiter or clinical suspicion of thyroid disease. 
Women with diabetes severe cardiovascular diseases and Systemic Lupus Erythematosus 
were not included in this study as they were usually attending specialist care units (Table 1). 
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6.1.2  HABP2 polymorphisms in women with recurrent miscarriage 
 Women with recurrent miscarriage 
Women (n = 165) with a diagnosis of recurrent miscarriage, during 1989 to 2009 were 
identified from outpatient registers, from the departments of Obstetrics and Gynecology at 
Uppsala University Hospital, Karolinska University Hospital (Huddinge and Solna), and 
Danderyd University Hospital. A careful review of medical journal of women with recurrent 
miscarriage was performed. All women with recurrent miscarriages had at least three or more 
consecutive miscarriages in the first or second trimester of pregnancy. Women with known 
risk factors for recurrent miscarriages such as, type I diabetes or other endocrine 
dysfunctions, Systemic Lupus Erythematosus, severe thrombophilia, and major chromosomal 
aberrations (in either partner) were excluded. Additionally, all women included in the study 
answered a questionnaire on reproductive health. 
Control women 
The control group (n = 289) were matched for age at their first pregnancy and consisted of 
heathy fertile women without previous history of miscarriage with at least one successful 
pregnancy. All women included in this study had conceived naturally and were of Caucasian 
ethnicity or European origin. 
 
6.1.3 Endometrial gene expression in women with recurrent miscarriage  
Women with recurrent miscarriage 
Women with recurrent miscarriage (n = 10) were recruited at departments of Obstetrics 
and Gynecology at Danderyd University Hospital from 2008-2013. The women with three or 
more verified consecutive miscarriages in the first or second trimester of pregnancy were 
included. Cases with obvious causes for recurrent miscarriages including chromosomal 
anomalies in the couple, uterine structural abnormalities, thrombophilic disorders and the 
presence of anti-phospholipid antibodies in serum were excluded. Additionally, women with 
disease linked to recurrent such as obesity, poorly controlled diabetes, thyroid disease or 
pelvic infections were excluded.  
 Control women  
Endometrial biopsies were obtained from healthy fertile women (n = 7) volunteers with 
regular menstrual cycles between 28 and 30 days. All samples were collected at the 
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department of Obstetrics and Gynecology at Danderyd University Hospital. These women 
were either undergoing laparoscopic sterilization or were recruited among the personnel in 
the hospital. All controls were fertile with at least one successful pregnancy and no history of 
recurrent miscarriage. All samples in both groups were collected at five to eight days after the 
LH surge (Table 1).  
  
6.1.4 Thyroid hormone in infertile women compared to fertile controls and thyroid 
associated protein in endometrium Fallopian tube and embryo 
 
6.1.4.1 TSH, fT4, and TPO-Ab serum levels in women with unexplained infertility 
compared to controls 
 
Women with unexplained infertility 
Serum levels of fT4, TSH and TPO-Ab were compared in women with unexplained 
infertility (n=147) and women with proven fertility (n = 67). All samples were collected at 
Kvinnohälsan, Karolinska University Hospital, Huddinge, at Danderyd University Hospital 
and at the Center of Reproduction at Uppsala University Hospital. All women included in this 
study were healthy and had a normal menstruation cycle between 28 to 32 days (Table 1). 
The couple with unexplained infertility had complete normal examinations with at least two 
normal semen analyses (based on WHO 2010 criteria). The women were normo-ovulatory 
had normal hormone analyses and normal tubal patency and no signs of endometriosis.   
Control women 
The control group was healthy volunteers with at least one child born after spontaneous 
conception 
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6.1.4.2    Endometrial biopsies from infertile and fertile women for detection of thyroid 
related proteins  
 
Women with unexplained infertility  
Endometrial biopsies from women with unexplained infertility (n = 19) were compared 
to endometrial biopsies from healthy fertile controls (n = 28) Samples from women with 
infertility were obtained at Kvinnohälsan, Karolinska University Hospital, Huddinge. All 
samples included in this study were collected during receptive phase (LH+ 6 to LH+ 8) 
(Table.1). 
Control women  
The women in control group (n = 28) were healthy with at least one child born after 
spontaneous conception. These women were enrolled at the Department of Obstetrics and 
Gynecology, Karolinska University Hospital, Huddinge. 
 
6.1.4.3  Fallopian tube in fertile women  
 
Fallopian tubes were collected from healthy volunteers (n = 13) with proven fertility, for 
detection of thyroid related protein during menstrual cycle. These women were attending 
Uppsala University Hospital for laparoscopic tubal sterilization or hysterectomy due to 
leiomyoma (Table 1).  
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Table 1. Characterization of study participants included in the study. Data is presented as 
median and range. Statistics according to Chi-square, Mann-Whitney rank sum test and Kruskal 
Wallis test.  
TSH during first trimester 
Serum samples Low risk 
(n = 511) 
High risk 
(n = 88) 
General 
(n = 699) 
p-value 
Age 33 (17 – 40) 35 (22 – 44) 30 (16 – 50) 0.001 
BMI 23 (17 – 46) 23 (15 – 34) - 0.718 
Polymorphism in HABP2 gene 
Blood samples Fertile 
(n = 289) 
Recurrent miscarriage 
(n = 165) 
 p-value 
Age 30.1 ± 5.8 30.3 ± 5.9  0.979 
Number of children 1.5 ±1.2 2.3 ± 0.96  <0.001 
Gene expression array  
Endometrial biopsies Fertile 
(n = 7) 
Recurrent miscarriage 
(n = 10) 
 p-value 
Age 37 (28 – 42) 36 (28 – 40)  0.417 
fT4, TSH, TPO-Ab 
Serum samples Fertile 
(n = 67) 
Infertile 
( n = 147) 
 p-value 
Age 36 (24 – 44) 34 (22 – 40)  0.899 
BMI 23 (18 – 33) 23 (17 – 37)  0.512 
TRα1, TRβ1, TSH R, DIO2, MCT8 
Endometrial biopsies Fertile 
(n = 28) 
Infertile 
( n = 19) 
 p-value 
Age 36 (25 – 41) 35 (31 – 39)  0.208 
BMI 25 (23 – 27) 22 (18 – 29)  0.475 
TRα1, TRβ1, TSH R, DIO2 
Fallopian tube Follicular phase 
(n = 6) 
Luteal phase 
(n = 7) 
 p-value 
Age 40 (37 – 44) 41 (39 – 46)  0.295 
BMI 29 (23 – 37) 28 (21 – 36)  0.413 
 
6.1.5 Human embryos 
 
The blastocyst stage human embryos (n = 74) were donated for research by couples 
undergoing in vitro fertilization treatment at Uppsala University Hospital. The embryos were 
suitable for transfer on thawing and graded by an experienced embryologist  
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METHODS  
 
6.1.6 TSH screening in early pregnancy 
 Blood samples from pregnant women were collected at the first visit at each antenatal 
care units. TSH levels were analyzed in serum according to clinical routine at Karolinska 
University Hospital in either Solna (Beckman Coulter AB, a chemiluminescent 
immunoenzymatic one-step sandwich assay) or Huddinge (immunoassay, Modular E 170; 
Roche). Subclinical hypothyroidism was defined according to locale clinical guideline at the 
time of study. 
 
6.1.7  Analysis of polymorphism in HABP2 in women with recurrent miscarriage 
 
Peripheral blood samples of women with recurrent miscarriage and controls were 
collected in EDTA tubes at each center and stored at − 20 °C until all samples were collected. 
After extraction of genomic DNA from whole blood in accordance to the QIAamp® DNA 
Blood Midi/Maxi handbook (QIAGEN, Netherlands), three polymorphisms in HABP2 gene; 
rs1157916 in the promoter area, rs2240879 in 5’UTR and rs7080536 (Gly534Glu) in exon 13 
were analyzed. Real-time PCR was carried out by use of TaqMan® SNP Genotyping Assays 
according to the manufactures instructions (Applied Biosystems, USA). The SNPs were 
chosen based on data from literature and from NCBI database. PCR was performed on Step 
One PlusTM Real-Time PCR System (Applied Biosystems, Foster City, USA).  
 
6.1.8 Endometrial gene expression in women with recurrent miscarriage  
  Collection of endometrial samples 
All endometrial biopsies were obtained during mid secretory phase. For determination of 
ovulation a self-testing luteinizing hormone (LH) test of the morning urine (Clearplan; 
Unipath Ltd., Bedford, United Kingdom). The ovulation was furthermore conformed by 
visualization of a corpus luteum by ultrasound and if it necessarily, by including 
measurement of elevated serum progesterone concentrations (>25 nmol/L). The biopsies 
were obtained using pipelle aspiration (Pipelle de Cornier, Laboratorie C.C.D., Paris, France). 
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The biopsies were then immediately placed in RNAlater (Qiagen, Hilden, Germany) and 
stored at 8°C for 24 h and thereafter at −20°C until further processing. All biopsies were used 
for gene expression by gene expression array. 
 
 Gene expression analyses 
Total RNA was isolated by use of miRNeasy, (Qiagen, Hilden, Germany) and 250 ng 
was used to generate amplified and biotinylated sense-strand cDNA. The arrays were then 
scanned using the GeneChip® Scanner 3000 7G Affymetrix. Raw data from the microarray 
analysis were normalized and the expressed genes were subsequently analyzed by the 
statistical computing language R (www.r-project.org) using packages available from the 
Bioconductor project (www.bioconductor.org). An empirical Bayes moderated paired t-test 
was used, the differently expressed genes between two groups were detected (p-value <0.05). 
The differently expressed genes by an average of log2 fold change of more than ±1 was 
selected. Cluster and principal component analysis were performed for visualization of 
differentially expressed genes by using genesis version 1.7.6 [124]. The functional analysis 
and gene ontology were studied by use of Database for Annotation, Visualization, and 
Integrated Discovery (DAVID) with the whole genome as background.  The networks of the 
differentially expressed genes were identified by used of Ingenuity Pathway Analysis (IPA) 
(Ingenuity® Systems, www.ingenuity.com).  
 
6.1.9 Thyroid hormone levels and thyroid related proteins in women with 
unexplained infertility compared to healthy controls 
 
TSH, f T4, TPO-Ab in serum 
Blood samples (serum) in fertile and infertile women were collected and stored at -20°C 
until analysis. All samples were analyzed by use of Enzyme linked immunosorbent assay 
(ELISA) according to instruction from manufacturer for fT4, TSH and TPO-Ab. 
 
Collection of endometrial samples  
All women included in this study were monitored by vaginal ultrasonography for 
evaluation of ovulation, by measuring the endometrial thickness and the leading follicle from 
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cycle day 10 until development of a corpus luteum; serum progesterone was measured in the 
mid-luteal phase. For determination of the day of the LH surge, a self-reporting luteinizing 
hormone (LH) test of the morning urine (Clearplan; Unipath Ltd., Bedford, United Kingdom) 
was used. Endometrial biopsies were obtained using Pipelle device as per standard protocols. 
All endometrial samples were immediately fixed in 4 % formaldehyde for a maximum 24 
hours and then stored in 70 % ethanol until embedding in paraffin. Endometrial biopsies were 
analyzed using immunostaining. The presence and distribution of TSHR, TRα, TRβ, DIO2 
and MCT8 was detected. 
 
Fallopian tube samples 
Fallopian tube samples were used for detection of TRα1, TRβ1, TSH R and DIO2 in 
different parts and compartments. These samples were obtained either during laparoscopic 
tubal sterilization or hysterectomy due to leiomyoma. Six samples were taken during the 
follicular phase (cycle day 1-13) and seven samples were during the luteal phase (cycle day 
14-28). The tissue samples were fixed in 4 % formaldehyde and then stored in 70 % ethanol 
until embedding in paraffin. Immunohistochemistry was used for detection of TSHR, TRα, 
TRβ and DIO2.  
 
Immunohistochemistry  
Immunohistochemistry was used for detection and location of thyroid related proteins in 
tissue from endometrium and Fallopian tube. In brief, a specific primary antibody interacts 
with an antigen in the tissue (Table 2). For detection a biotinylated secondary antibody 
conjugated and thereafter visualized by enzymatic activation of a chromogenic substrate was 
used. 
 
6.1.9.1 Embryo Culture 
Frozen-thawed embryos were used. After thawing, the embryos were randomly allocated 
to be cultured in standard media with T4 added to a final concentration of 20 pmol/L (n=38) 
or in standard culture media (n= 36) until day 6 and thereafter blastocyst formation was 
determined according to Gardener, based on blastocyst development, quality of inner cell 
mass and quality of trophectoderm.  
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Table 2. Antibodies used in immunohistochemistry. 
Antibody Receptor Concentration  
Polyclonal Rabbit IgG TRα1 5 µg/ml 
Monoclonal mouse IgG  TRα2 5 µg/ml 
Polyclonal Rabbit IgG  TRβ1 3 µg/ml 
Monoclonal mouse IgG  TSHR 2.5 µg/ml 
Polyclonal Rabbit IgG DIO2 50 µg/ml 
Polyclonal Rabbit IgG MCT8 50 µg/ml 
 
For evaluation of immunohistochemistry, two observers evaluated the staining intensity of 
each sample. Staining intensity and the number of stained cells were graded according to the 
following: 0 = no staining, + = faint staining, ++ = moderate staining, and +++ = strong 
staining. 
 
6.1.10 Statistical Analysis 
 
For descriptive statistics, independent t-test or Mann-Whitney Rank Sum Test were used. For 
comparisons between three or more groups, chi-square test was used in the study I, II, III and 
Kruskal-Wallis test followed by Dunn's test was used in the study IV. For differences within 
or between groups in study II one-way ANOVA Test was used and for allele frequencies 
deviations from Hardy-Weinberg equilibrium were investigated. In study III non-parametric 
correlations were tested according to Spearman’s rank correlation. For the number of median 
and good quality embryos, Fischer’s exact test was used. All differences with p values ≤ 0.05 
were considered statistically significant. 
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7.  RESULTS  
 
7.1.1 Incidence of hypothyroidism and subclinical hypothyroidism in early 
pregnancy 
 
The incidence of subclinical hypothyroidism and hypothyroidism was almost the same, 
(almost 10), in all three groups regardless of TSH levels ≥ 2.0 mIU/L or ≥ 2.5 mIU/L in early 
pregnancy (Figure 10).  
 
 
 
 
Figure 10. Flow diagram of study population of early pregnant women and the incidences of 
subclinical hypothyroidism and hypothyroidism  
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Hypothyroid women on LT4 treatment prior to pregnancy (n=77) had in 50.6 % of cases a 
TSH level ≥ 2.0 mIU/L and in 36.4 % of cases a TSH levels ≥ 2.5 mIU/L. 
During this study, all women with subclinical hypothyroidism were treated with LT4 and 
monitored with control of fT4, TSH during pregnancy with a goal of treatment at TSH level < 
2.0 mIU/L.  
 
7.1.2 Polymorphism in HABP2 genes in women with recurrent miscarriage 
 
In the present study, there were no significant differences in the three studies 
polymorphisms of the HABP2 gene observed between women with recurrent miscarriage and 
fertile controls. However, the rs1157916A allele showed a tendency to be more frequent 
among women with recurrent miscarriage (P = 0.058). 
The majority of women with recurrent miscarriage (77 %) eventually had a full-term 
pregnancy with at least one child successfully born. Women with five or more miscarriages 
had less chance, 26.2%, of a successful pregnancy. The live birth rate in study population is 
shown in table 3.  
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Table 3.  Table shows live birth in study population, unexplained recurrent miscarriage (RM) and control.      Data is presented as mean + SD, RM divided in three 
groups due to age 
 
 
 Recurrent miscarriage Control 
Age at first miscarriage 21.2 + 2.3  29.8 + 2.7  37.3 + 1.8  All   
No. of patients n, (%) 27 (16.4 %) 95 (57.6 %) 43 (26.0 %) 165 289 
Children before miscarriage 4 (14.8 %) 31 (32.6 %) 17 (39.5 %) 52 (31.5 %) NA 
No. of miscarriages  (mean+ SD) 5.6 + 3.7 4.6 + 2.0 4.9 + 2.1 4.9 + 2.4 NA 
No. of miscarriages in a row 4.9 + 3.4 4.2 + 1.9 4.5 + 1.8 4.4 + 2.2 NA 
Children after miscarriage 15 (55.5 %) 82 (86.3 %) 30 (69.8 %) 127 (77.0 %) NA 
No. of pregnancies 6.6 + 3.9 6.4 + 2.3 6.2 + 2.2 6.4 + 2.6 2.3 + 0.9 
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7.1.3 Differential gene expression in endometrium of women with recurrent 
miscarriage and its’ biological relevance  
 
Microarray and IPA 
In total, 124 genes were differently expressed in women with recurrent miscarriage, with 30 
genes were up- regulated and 94 genes downregulated by a minimum of two-fold in women 
with recurrent miscarriage compared to fertile controls. The differently expressed shown 
genes in to groups have been visualized by using a heat map in (Figure 11).  
 
 
Figure 11. The figure shows Heat map of gene expression in the receptive endometrium from 
four women with recurrent pregnancy loss and five control women. Green represents down-
regulated genes and red represents up-regulated genes.  
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Of the differently expressed genes in women with recurrent miscarriage, 67 % (19 of 27) 
were related to immune and inflammatory processes. The IPA analysis showed that the most 
interesting network was “Reproductive system disease” with IL8 in center of this network 
(Figure 12). The most up regulated gene was Olfactomedin 4 (OLFM4) and the two most 
down regulated genes were progestogen-associated endometrial protein (PAEP) and 
Stanniocalcin 1 (STC1), the latter well known for being related to endometrial receptivity.  
 
 
 
Figure 12 .The highest score after IPA analysis of endometrium from women with recurrent 
miscarriage compared and from control women was “Reproductive system disease“. Down-
regulated genes are indicated as green while up- regulated genes are indicated as red.  
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7.1.4 Thyroid hormone and thyroid hormone related proteins in 
endometrium, Fallopian tube and embryo  
 
   TSH, fT4 and TPO-Ab in unexplained infertile women compared with fertile controls 
Women with unexplained infertility had significantly higher serum levels of fT4. There were 
no significant differences in the serum levels of TSH and TPO-Ab between the groups. 
 
  Protein staining of TSH R, TRα1, TRβ1, DIO2 and MCT8 in endometrium from 
unexplained infertile women and fertile controls 
 
The highest protein staining of TSH R, TRα1 and TRβ1 was identified in the luminal 
epithelium. There was significantly lower protein staining of TRα1 and MCT8 in endometrial 
glandular epithelium from women with unexplained infertility compared to endometrium 
from fertile controls (Figure 13) 
 
 Figure 13. Endometrial protein staining of TSH R (a), TRα1 (b), TRβ1 (c), DIO2 (d) and MCT8 
(e) in endometrium from women with unexplained infertility compare to controls. The staining 
intensity was generally higher in the luminal epithelium (LE) followed by the glandular epithelium 
(GE) and the least intense staining was seen in the stroma (St). Statistical differences were 
calculated according to Kruskal-Wallis U-test, p < 0.05 was considered statistical difference (*). 
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Protein staining of TSH R, TRα1, TRβ1 and DIO2 in the Fallopian tube 
 
Staining of proteins related to the thyroid hormone system was seen in the Fallopian tube. 
The TSH R, TRα1, TRβ1 and DIO2 proteins were identified in the epithelium, muscle and 
vessels with the highest staining in the epithelium, p <0.001 (Figure 14 and 15). There was no 
difference between the istmus, ampulla and fimbrie and there was no difference between the 
follicular and luteal phases of the menstrual cycle.  
 
Figure 14. The immune staining intensity of TSH R (a), TRα1 (b), TRβ1 (c) and DIO2 (d) in the three 
compartments of Fallopian tube from fertile women. The staining intensity of TSH R, TRα1, TRβ1 and 
DIo2 was significantly different in all three compartments of fallopian tubes; Epithelial cells (E), 
Vessels (V), Muscle (M). Statistics according to Kruskal-Wallis one-way analysis of variance on ranks 
followed by Dunn’s test, p < 0.001 (***) was considered statistical difference. 
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Figure 15. Representative microscopic photos of immunohistochemical staining of a) TSHR, b) 
TR, c) TR, d) DIO2 and e) MCP8 in endometrium and g) TSHR, h) TR, i) TR and j) DIO2 in 
Fallopian tube. Negative control was performed by omission of the primary antibody as seen in f) 
endometrium and k) Fallopian tube. Magnification was 400X.  
 
 Thyroid hormone and embryo development 
 
After addition of T4 to the culture media, the number of good quality embryos, was 
significantly higher in the T4 treated group, 25 (65 %), compared to embryo in control group 
18 (50 %, p = 0.031, Figure 16). 
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  Figure 16. Number of embryos that reached a good quality blastocyst in the control group, (C), 
and in the thyroid hormone treated group, (T). Statistics according to Fischer’s exact test was 
calculated on the percentage of medium and good quality embryos, p < 0.05 was considered 
statistical difference.  
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8. DISCUSSION  
It is well known that thyroid dysfunction has a negative influence on female fertility and 
also increasing evidence of a correlation between untreated thyroid dysfunction and adverse 
pregnancy outcome both for the pregnant woman and the growing fetus [40, 44, 46, 53, 125]. 
This highlights the importance of a proper screening model for detection of thyroid 
dysfunction during early pregnancy. 
Our study showed almost the same incidence of SCH and hypothyroidism (9.6 % and 10.2 
%) in all pregnant women regardless of risk for thyroid disease. This confirms the results of a 
previous study conducted in Uppsala community in Sweden [126], which showed similar 
incidences of elevated TSH both in a target screening group (12.1 %), and in an unselected 
screening group (12.6 %). Furthermore, a Cochrane review of different screening methods for 
TSH during early pregnancy showed that the number of women diagnosed and subsequently 
treated for thyroid dysfunction is increased after general screening [127].  
A few concerns have been raised about treatment with LT4 in a high percentage of pregnant 
women. One consideration is the cost benefit of treatment since the evidence for treatment is 
not conclusive. There are three prospective randomized studies on this aspect; only two 
studies have evaluated the impact of treatment on fetal neurodevelopment. None of them 
showed any significant improvement in IQ in the children. However, none of these studies 
has evaluated the impact of treatment during the first trimester of pregnancy. [47, 128, 129]. 
The fact that several previous observational and retroactive studies have shown a correlation 
between SCH and adverse maternal and fetal complications highlights the complexity of this 
context. [46, 130-132]  
One other consideration is the possible adverse effect of LT4 treatment on the developing 
fetus. The risk of treatment with LT4 during pregnancy has been considered minimal [133].   
A study based on the Swedish Birth Register showed a slightly higher risk for congenital 
malformations, anal and anorectal atresia, in children born to women on LT4 
supplementation. However, women on LT4 treatment showed a higher incidence of other 
diseases such as cardiovascular disease and psychological diagnosis like depression. The 
Malformations in these categories may have association with other treatments or the 
underlying diseases, including hypothyroidism. [134].  
Moreover, our study highlights the importance of early adjustment of therapy in women with 
hypothyroidism on LT4 treatment. In 50 % of cases, the women on LT4 treatment had 
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suboptimal LT4 treatment. This is in agreement with previous studies by Hallengren et al. 
and Vadiveloo et al., who reported that 30 % of women on LT4 treatment had suboptimal 
treatment [135, 136].  The fetus is totally dependent on maternal thyroid hormone during first 
trimester of pregnancy. Thus, it is of importance to increase doses of LT4 as soon as the 
pregnancy is confirmed [137].  
There is an ongoing debate on normal upper limit of TSH during pregnancy and benefits of 
thyroxine therapy in women with SCH. The profound change in thyroid physiology during 
pregnancy requires different reference values for fT4 and TSH [51]. International guidelines 
have recommended assessment of trimester specific population-based reference ranges [138]. 
In the absence of such reference values, use of international trimester specific cut-off levels is 
recommended [133].  
In our study, the use of TSH 2.0 mIU/L as cut-off level was based on local clinical guidelines 
for treatment of LT4 at the time of the study. In 2017, the previous recommendation for the 
upper limit of serum TSH levels during the first trimester was changed from TSH 2.5 mIU/L 
to 3.5 mIU/L by the American Thyroid Association [133]. However, a cut-off level of TSH < 
2.5 mIU/L has been recommended for women with overt hypothyroidism on LT4 
supplementation [133]. The Swedish guidelines for treatment of SCH during pregnancy now 
include an upper limit of TSH at 3.5 mIU/L during the first trimester and general screening 
during early pregnancy has been recommended (http://online.liebertpub.com/doi/ 
pdfplus/10.1089/thy.2016.0457).    
An association between polymorphism in HABP2 gene with unexplained infertility has been 
observed in a previous study [102]. Since HABP2 protein in endometrial epithelial cell is up 
regulated during the mid-secretory phase, it has been identified as a putative biomarker of 
receptive endometrium [91]. Therefore, as it can be assumed that recurrent miscarriage might 
be related to endometrial receptivity failure, the association between recurrent miscarriage 
and polymorphism in HABP2 gene was studied. The three studied SNPs in the HABP2 gene 
were similar in women with recurrent miscarriage and controls. However, we also observed 
that a polymorphism in the promotor region, rs1157916, was more frequent among women 
with recurrent miscarriage than in the control group.  
Furthermore, this study showed that women with recurrent miscarriage have a high chance of 
successful pregnancy, almost 80%, but that the number of previous miscarriages, five or 
more, had a negative impact on the live birth rate, which is in line with the results of other 
studies.[139, 140]. The limitation of our study was a relative short follow-up times, two 
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years, that may influence the results. Therefore, additional studies are required to clarify the 
relationship between HABP2 and recurrent miscarriage.  
In a comparison of almost 30 000 genes expressed in receptive endometrium between women 
with recurrent miscarriage and fertile controls, a different expression pattern was seen. In 
total, 124 genes were expressed differently in women with recurrent miscarriage. Functional 
analysis of these genes revealed that most of the dysregulated genes were involved in 
immune response and inflammatory processes. Particularly, the inflammatory mediator, IL8 
gene expression was up regulated in women with recurrent miscarriage. Inflammatory 
mediators play an important role in implantation, probably by involvement in the selection of 
a good quality embryo [141] 
The highest difference was seen for OLFM4, STC1 and PAEP. These proteins are known to 
be associated with implantation. OLFM4 is an estrogen regulated protein and seems to be 
involved in tissue remodeling of the endometrium before implantation. PAEP has suppressive 
effects of trophoblast activity during implantation and can also modulate trophoblast activity. 
[142].  
Although the majority of early miscarriages is associated with abnormal embryo karyotype, 
women with many miscarriages have high frequency of embryos with normal karyotype 
[143]. It has been suggested that an impaired endometrial decidualization in women with 
recurrent miscarriage facilitates implantation of embryos of poor quality that subsequently 
leads to miscarriage [144].  
In the present study, women with unexplained infertility showed a slightly higher level of 
serum fT4 and reduced protein staining of TRα1 and MCT8. The lower levels of TRα1 in 
endometrium from infertile women might require higher levels of fT4. It has been shown that 
thyroid hormone supplementation in rats increase the expression of TRα and TRβ in the 
uterus [145].  
In addition, lower levels of MCT8 were found in both endometrial glandular epithelial and 
stromal cells in infertile women. The action of thyroid hormone is dependent on intra-cellular 
transport (ref). The reduced levels of TRα1 might be a result of low intracellular levels due to 
reduced levels of transport proteins. 
Furthermore, the present study showed higher levels of MCT8 protein during the mid-luteal 
phase, which indicates that intracellular transport of TH into the epithelial cells might be 
important for normal receptivity of the endometrium.  
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The presences of different proteins that are involved in the direct actions of the thyroid 
system on the Fallopian tubes in combination with enhanced embryo development under T4 
substitution, indicate a physiological role of thyroid hormone during early embryo 
development. Furthermore, in a systematic review, it was shown that sufficient treatment with 
LT4 in women undergoing IVF/ICSI improved of take home baby rate. Therefore, LT4 
supplementation for women with SCH and/or thyroid autoimmunity who are undergoing 
fertility treatment is needed [146].  
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9. SUMMARY AND CONCLUSIONS  
 
SUMMARY 
 
 High-risk screening is not optimal to determine which women are at risk of thyroid 
disease during early pregnancy.  Sufficient treatment with LT4 during early 
pregnancy is important in women with known hypothyroidism.   
 There was no association between SNPs in the HABP2 gene and recurrent 
miscarriages. However, women with recurrent miscarriage have good prognosis 
for subsequent live birth.  
 Differently expressed endometrial genes in women with recurrent miscarriages 
emphasize the importance of normal development into a receptive endometrium, 
required for normal embryo implantation.  
 The Thyroid system seems to be imbalanced in women with unexplained 
infertility.  
 The presence of TRα1, TRβ1 and TSH R, and the thyroid hormone related 
proteins, MCT8 and D2 in the Fallopian tubes in combination with improvement 
of embryo development by T4 treatment show that thyroid hormones are important 
for early embryo development.  
 
CONCLUSIONS 
 
Adequate diagnosis and treatment of thyroid disease in women that are either pregnant 
or trying to become pregnant is of importance for successful pregnancy outcome. 
It is likely that recurrent miscarriage is associated with aberrant inflammatory response 
rather than polymorphism in the HABP2 gene.   
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10. FUTURE PERSPECTIVE 
 
 To establish a trimester specific population based TSH reference range in Stockholm. 
 To clarify possible genetic associations with recurrent miscarriage, recently 
developed methods like whole genome sequencing would assist in clarifying this.  
 The exact mechanisms behind thyroid disturbances and fertility problems are still not 
known and further studies on thyroid-related proteins and the reproductive system is 
needed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  58 
11. SAMMANFATTNING PÅ SVENSKA 
 
Oförklarad barnlöshet drabbar 10-15 % av alla par, som vill ha barn. Upprepade missfall, 
(fler än 3), inträffar hos 1 till 3 % av alla gravida kvinnor och orsaken är okänd hos 50 %. 
Rubbningar i sköldkörtelfunktionen kan orsaka barnlöshetsproblem hos kvinnor. 
Avsikten med den här avhandlingen var att studera sköldkörtelfunktionens och 
livmoderslemhinnans betydelse för implantation och graviditet och effekten av 
sköldkörtelhormon på human embryoutveckling. 
Förekomsten av rubbningar av sköldkörtelfunktionen studerades i tre grupper av kvinnor i 
tidig graviditet. En hög risk, en låg risk och en normal risk för att utveckla underfunktion i 
sköldkörteln. Subklinisk underfunktion förelåg, då TSH-nivåerna var högre än 2,5 mIE/L. 
Det förelåg ingen skillnad mellan grupperna.  
Kvinnor med upprepade missfall och kontroller, inkluderades i dels i en genetisk analyser i 
HABP2-genen och dels genom att studera genuttryck i livmoderslemhinnan. Inga skillnader i 
HABP2-genen kunde påvisas mellan grupperna. Totalt 124 gener uttrycktes olika i 
livmoderslemhinna från kvinnor med upprepade missfall jämfört med kontroller. Dessa gener 
var huvudsakligen involverade i immunologiska processer, speciellt genom uppreglering av 
IL8.  
Hos kvinnor med oförklarad barnlöshet och kontroller studerades sköldkörtel relaterade 
proteiner i livmoderslemhinnan och äggledarna. Kvinnor med oförklarad barnlöshet hade 
lägre nivåer av TRα1 och MCT 8 i livmoderslemhinnan än kontrollerna. Man kunde även se 
infärgning av färgning av sköldkörtelrelaterade proteiner i äggledarna. 
Humana embryon användes för att studera effekterna på utvecklingen av embryot.  En grupp 
embryon behandlades med sköldkörtelhormon och den andra gruppen var kontroller. I 
behandlingsgruppen såg man en förbättrad embryoutveckling jämfört med de obehandlade 
kontrollerna. 
Sammanfattningsvis: En allmän screening av sköldkörtel funktionen av alla kvinnor i tidig 
graviditet bör införas, (vilket numera är infört i Sverige), 
Det krävs fler och större studie för att kartlägga sköldkörtelns betydelse för fruktsamhet, 
graviditet och embryo utveckling.  
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